Prostate cancer is the most commonly diagnosed cancer in the United States. Prostate cells contain vitamin D receptors as well as enzymes necessary for vitamin D metabolism. Vitamin D metabolites have an antiproliferative and a pro-differentiating effect on prostate cancer cell lines in vitro and in vivo. As a result, there has been an emerging interest in the potential role of vitamin D in the etiology of prostate cancer. This review summarizes all available epidemiological literature on the association between dietary vitamin D, circulating levels of vitamin D and sunlight exposure in relation to prostate cancer risk. To place these studies in context, we also provide some background information on vitamin D, such as its dietary sources, metabolism, optimal levels, hypovitaminosis and relationship with the prostate.
Your institute does not have access to this article
Open Access articles citing this article.
Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan
Scientific Reports Open Access 12 October 2021
Subscribe to Journal
Get full journal access for 1 year
only $24.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bono AV . The global state of prostate cancer: epidemiology and screening in the second millennium. BJU Int 2004; 94 (Suppl 3): 1–2.
Brawley OW, Barnes S . The epidemiology of prostate cancer in the United States. Semin Oncol Nurs 2001; 17: 72–77.
Chodak G . Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 2006; 8 (Suppl 2): S3–S8.
Damber JE . Prostate cancer: epidemiology and risk factors. Curr Opin Urol 1998; 8: 375–380.
Gronberg H . Prostate cancer epidemiology. Lancet 2003; 361: 859–864.
Hsing AW, Chokkalingam AP . Prostate cancer epidemiology. Front Biosci 2006; 11: 1388–1413.
Scardino PT, Weaver R, Hudson MA . Early detection of prostate cancer. Hum Pathol 1992; 23: 211–222.
Trinchieri A, Moretti R . Trends in prostate cancer epidemiology in the year 2000. Arch Ital Urol Androl 2005; 77: 164–166.
Wilt TJ . Prostate cancer: epidemiology and screening. Rev Urol 2003; 5 (Suppl 6): S3–S9.
Ruijter E, van de KC, Miller G, Ruiter D, Debruyne F, Schalken J . Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22–45.
Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case–control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795–804.
Lee MM, Wang RT, Hsing AW, Gu FL, Wang T, Spitz M . Case–control study of diet and prostate cancer in China. Cancer Causes Control 1998; 9: 545–552.
Veierod MB, Laake P, Thelle DS . Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997; 73: 634–638.
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571–1579.
Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25–34.
Nomura AM, Kolonel LN . Prostate cancer: a current perspective. Epidemiol Rev 1991; 13: 200–227.
Brawn PN, Johnson EH, Kuhl DL, Riggs MW, Speights VO, Johnson CF et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993; 71: 2569–2573.
Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S . Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000; 82: 1585–1592.
Ogunbiyi JO, Shittu OB . Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc 1999; 91: 159–164.
Osegbe DN . Prostate cancer in Nigerians: facts and nonfacts. J Urol 1997; 157: 1340–1343.
Buschemeyer III WC, Freedland SJ . Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331–343.
Hanchette CL, Schwartz GG . Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861–2869.
Routh JC, Leibovich BC . Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005; 80: 899–907.
Dennis LK, Hayes RB . Alcohol and prostate cancer. Epidemiol Rev 2001; 23: 110–114.
John EM, Dreon DM, Koo J, Schwartz GG . Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89–90: 549–552.
John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA . Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470–5479.
John EM, Koo J, Schwartz GG . Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev 2007; 16: 1283–1286.
Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641–642.
Ekman P, Pan Y, Li C, Dich J . Environmental and genetic factors: a possible link with prostate cancer. Br J Urol 1997; 79 (Suppl 3): 35–41.
Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW . Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995; 6: 235–239.
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.
Gronberg H, Damber L, Damber JE . Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152: 1484–1487.
Krain LS . Some epidemiologic variables in prostatic carcinoma in California. Prev Med 1974; 3: 154–159.
Woolf CM . An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739–744.
Ghadirian P, Howe GR, Hislop TG, Maisonneuve P . Family history of prostate cancer: a multi-center case–control study in Canada. Int J Cancer 1997; 70: 679–681.
Hickey K, Do KA, Green A . Smoking and prostate cancer. Epidemiol Rev 2001; 23: 115–125.
Peterson HB, Howards SS . Vasectomy and prostate cancer: the evidence to date. Fertil Steril 1998; 70: 201–203.
Lee IM, Sesso HD, Chen JJ, Paffenbarger Jr RS . Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev 2001; 23: 132–137.
Blutt SE, Weigel NL . Vitamin D and prostate cancer. Proc Soc Exp Biol Med 1999; 221: 89–98.
Feldman D, Zhao XY, Krishnan AV . Vitamin D and prostate cancer. Endocrinology 2000; 141: 5–9.
Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM . Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 1996; 223: 141–146.
Strugnell SA, Deluca HF . The vitamin D receptor—structure and transcriptional activation. Proc Soc Exp Biol Med 1997; 215: 223–228.
Wang X, Chen X, Akhter J, Morris DL . The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Br J Urol 1997; 80: 260–262.
Zhuang SH, Schwartz GG, Cameron D, Burnstein KL . Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997; 126: 83–90.
Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP . 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6: 727–732.
Skowronski RJ, Peehl DM, Feldman D . Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952–1960.
Zhuang SH, Burnstein KL . Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998; 139: 1197–1207.
Gross C, Stamey T, Hancock S, Feldman D . Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035–2039.
Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ . Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003; 133: 2425S–2433S.
Giovannucci E . The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005; 16: 83–95.
Holick MF . Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 2008; 3: 1548–1554.
Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R . Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68: 854–858.
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86:888–894.
Mehta RG, Mehta RR . Vitamin D and cancer. J Nutr Biochem 2002; 13: 252–264.
Nishimura A, Shinki T, Jin CH, Ohyama Y, Noshiro M, Okuda K et al. Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 1994; 134: 1794–1799.
Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA . Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108–4110.
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R . Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713–716.
Hollis BW . Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317–322.
Bischoff-Ferrari HA . Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008; 624: 55–71.
Lips P . Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477–501.
McKenna MJ . Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992; 93: 69–77.
Das G, Crocombe S, McGrath M, Berry JL, Mughal MZ . Hypovitaminosis D among healthy adolescent girls attending an inner city school. Arch Dis Child 2006; 91: 569–572.
Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212–1221.
Sullivan SS, Rosen CJ, Halteman WA, Chen TC, Holick MF . Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc 2005; 105: 971–974.
Yanoff LB, Parikh SJ, Spitalnik A, Denkinger B, Sebring NG, Slaughter P et al. The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf) 2006; 64: 523–529.
Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S . Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 1985; 76: 370–373.
de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS . 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69–77.
Chatfield SM, Brand C, Ebeling PR, Russell DM . Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J 2007; 37: 377–382.
Olmez D, Bober E, Buyukgebiz A, Cimrin D . The frequency of vitamin D insufficiency in healthy female adolescents. Acta Paediatr 2006; 95: 1266–1269.
Goswami R, Gupta N, Goswami D, Marwaha RK, Tandon N, Kochupillai N . Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. Am J Clin Nutr 2000; 72: 472–475.
Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS . Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 2005; 98: 667–676.
Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S . Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577–582.
Plotnikoff GA, Quigley JM . Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78: 1463–1470.
Rovner AJ, O'Brien KO . Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med 2008; 162: 513–519.
Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ . Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158: 531–537.
Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR . Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30: 771–777.
Tangpricha V, Pearce EN, Chen TC, Holick MF . Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112: 659–662.
Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P . Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 847–852.
Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 1992; 52: 515–520.
Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P . Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000; 86: 40–46.
Tsai MJ, O'Malley BW . Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451–486.
Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR . Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001; 2: 203–216.
Zhao XY, Ly LH, Peehl DM, Feldman D . Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140: 1205–1212.
Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP . 5,6-Trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 1999; 59: 4023–4029.
Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S . Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996; 1: 97–101.
Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652–661.
De Stefani E, Deneo-Pellegrini H, Boffetta P, Ronco A, Mendilaharsu M . Alpha-linolenic acid and risk of prostate cancer: a case–control study in Uruguay. Cancer Epidemiol Biomarkers Prev 2000; 9: 335–338.
Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ . Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994; 86: 281–286.
Godley PA, Campbell MK, Miller C, Gallagher P, Martinson FE, Mohler JL et al. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 1996; 5: 115–119.
Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L . Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 1997; 71: 545–551.
Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A . Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998; 9: 559–566.
Grant WB . Calcium, lycopene, vitamin D and prostate cancer. Prostate 2000; 42: 243.
Schwartz GG, Hulka BS . Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10: 1307–1311.
Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000; 11: 859–867.
Tavani A, Bertuccio P, Bosetti C, Talamini R, Negri E, Franceschi S et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005; 48: 27–33.
Tseng M, Breslow RA, Graubard BI, Ziegler RG . Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005; 81: 1147–1154.
Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN . Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007; 166: 1259–1269.
Huncharek M, Muscat J, Kupelnick B . Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 2008; 60: 421–441.
Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16: 2623–2630.
Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002; 60: 1118–1123.
Kristal AR, Cohen JH, Qu P, Stanford JL . Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 719–725.
Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: e103.
Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998; 9: 425–432.
Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N et al. Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst 2008; 100: 796–804.
Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E . Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15: 255–265.
Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer 2004; 108: 104–108.
Clemens TL, Adams JS, Henderson SL, Holick MF . Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1: 74–76.
Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ . Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121–126.
Lund B, Sorensen OH . Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population. Scand J Clin Lab Invest 1979; 39: 23–30.
McLaughlin M, Raggatt PR, Fairney A, Brown DJ, Lester E, Wills MR . Seasonal variations in serum 25-hydroxycholecalciferol in healthy people. Lancet 1974; 1: 536–538.
Stamp TC, Round JM . Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 1974; 247: 563–565.
Robsahm TE, Tretli S, Dahlback A, Moan J . Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15: 149–158.
Walsh PC . Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Urol 2005; 173: 87.
Schwartz GG . Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology 1992; 11: 244–254.
Rukin NJ, Zeegers MP, Ramachandran S, Luscombe CJ, Liu S, Saxby M et al. A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma. Br J Cancer 2007; 96: 523–528.
de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW . Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol 2007; 165: 966–972.
Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer 2007; 43: 1701–1712.
Colli JL, Grant WB . Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology 2008; 71: 531–535.
Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen 2004; 43: 121–127.
Moon SJ, Fryer AA, Strange RC . Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res 2005; 571: 207–219.
Bodiwala D, Luscombe CJ, Liu S, Saxby M, French M, Jones PW et al. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett 2003; 192: 145–149.
Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001; 85: 1504–1509.
Mucci LA, Spiegelman D . Vitamin D and prostate cancer risk—a less sunny outlook? J Natl Cancer Inst 2008; 100: 759–761.
Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 2005; 14: 586–589.
This study was funded by Cancer Treatment Centers of America®.
About this article
Cite this article
Gupta, D., Lammersfeld, C., Trukova, K. et al. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 12, 215–226 (2009). https://doi.org/10.1038/pcan.2009.7
- vitamin D
Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan
Scientific Reports (2021)
Altered expression of cytochrome P450 enzymes involved in metabolism of androgens and vitamin D in the prostate as a risk factor for prostate cancer
Pharmacological Reports (2020)
Food Biophysics (2014)
The roles of ultraviolet-B irradiance, vitamin D, apolipoprotein E ε4, and diet in the risk of prostate cancer
Cancer Causes & Control (2011)
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
Cancer Causes & Control (2011)